Brief: PolyPid Announces Successful Completion Of Enrollment In Phase 3 Shield II Trial Of D-Plex₁₀₀ For The Prevention Of Abdominal Colorectal Surgical Site Infections
11/03/2025 11:03
March 11 (Reuters) - PolyPid Ltd PYPD.O: POLYPID ANNOUNCES SUCCESSFUL COMPLETION OF ENROLLMENT IN PHASE 3 SHIELD II TRIAL OF D-PLEX₁₀₀ FOR THE PREVENTION OF ABDOMINAL COLORECTAL SURGICAL SITE INFECTIONS POLYPID LTD - TOP-LINE RESULTS EXPECTED BY END OF Q2 2025 Source text: ID:nGNX3gKXWG Further company coverage: PYPD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Polypid
See all newsPolyPid Ltd reports results for the quarter ended June 30 - Earnings Summary
PolyPid Ltd expected to post a loss of 38 cents a share - Earnings Preview
Brief: Polypid Announces FDA Acceptance Of NDA With Priority Review For D-Plex₁₀₀
PolyPid, Azurity sign surgical site infection drug deal
Brief: Polypid Initiates D-Plex₁₀₀ NDA Submission To The FDA